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Ex-situ normothermic machine perfusion (NMP) of transplant kidneys allows assessment
of kidney quality and targeted intervention to initiate repair processes prior to
transplantation. Mesenchymal stromal cells (MSC) have been shown to possess the
capacity to stimulate kidney repair. Therefore, the combination of NMP and MSC therapy
offers potential to repair transplant kidneys. It is however unknown how NMP conditions
affect MSC. In this study the effect of NMP perfusion fluid on survival, metabolism and
function of thawed cryopreserved human (h)MSC and porcine (p)MSC in suspension
conditions was studied. Suspension conditions reduced the viability of pMSC by 40% in
both perfusion fluid and culture medium. Viability of hMSC was reduced by suspension
conditions by 15% in perfusion fluid, whilst no differences were found in survival in
culture medium. Under adherent conditions, survival of the cells was not affected by
perfusion fluid. The perfusion fluid did not affect survival of fresh MSC in suspension
compared to the control culture medium. The freeze-thawing process impaired the
survival of hMSC; 95% survival of fresh hMSC compared to 70% survival of thawed
hMSC. Moreover, thawed MSC showed increased levels of reactive oxygen species,
which indicates elevated levels of oxidative stress, and reduced mitochondrial activity,
which implies reduced metabolism. The adherence of pMSC and hMSC to endothelial
cells was reduced after the thawing process, effect which was particularly profound in in
the perfusion fluid. To summarize, we observed that conditions required for machine
perfusion are influencing the behavior of MSC. The freeze-thawing process reduces
survival and metabolism and increases oxidative stress, and diminishes their ability
to adhere to endothelial cells. In addition, we found that hMSC and pMSC behaved
differently, which has to be taken into consideration when translating results from animal
experiments to clinical studies.
Keywords: mesenchymal stromal cells, normothermic machine perfusion, kidney repair, endothelial cells,
suspension conditions, perfusion fluid, cryopreservation
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INTRODUCTION
As the outcome of kidney transplantation has improved, the
demand for kidney transplantation has increased and the donor
organ pool to date is too small to supply the current need for
transplant organs. The shortage in available donor kidneys (1)
has led to the use of expanded criteria donor organs, that includes
kidneys from older donors or from donors with hypertension,
suboptimal kidney function or death resulting from stroke (2).
This has resulted in a higher decline rate at time of offering and
may also lead to a poorer outcome of the transplantation (3).
Currently, several techniques are being employed to improve
the quality of expanded criteria kidneys and discarded kidneys
to make them suitable for transplantation, including machine
perfusion. Hypothermic machine perfusion of donor kidneys
implies connection of the organ to a pump that perfuses the organ
with a solution that provides the required components needed to
maintain viability while also removing waste products released as
a result of the metabolism and perfusion injury of the organ.
A more physiological way to assess viability of donor organs
is continuous perfusion at normothermic temperature at 37◦C
with proper oxygenation and in the presence of necessary
nutrients. A few years ago, the clinical feasibility and safety of 1 h
normothermic machine perfusion (NMP) was demonstrated (4).
Other groups decided to evaluate the feasibility of longer term
NMP at 37◦C, allowing more time to observe the kidney as well
as intervene where possible. Recently, NMP has been successfully
tested in a series of discarded donor kidneys for up to 24 h (5, 6).
During NMP, using a bespoke red blood cell (RBC) enriched
oxygenated and nutrient containing perfusate, the metabolism of
the kidney resumes and allowsmonitoring during perfusion prior
to transplantation (6, 7). Application of NMP for assessment and
targeted intervention (8) to improve kidney quality is appealing
and the effect of the therapy can potentially be monitored before
the organ is transplanted. Thus, NMP is postulated as a promising
platform to reduce kidney damage and initiate regeneration prior
to transplantation.
Mesenchymal stromal cells (MSC) are multipotent cells which
are found in adult tissues where they support function and
repair (9). The International Society for Cellular Therapy has
established the minimum criteria that a cell must meet to be
considered an MSC: in vitro attachment to plastic, expression
of several cell surface markers including CD29, CD44, CD90,
the absence of endothelial and hematopoietic markers and the
capacity to differentiate into cell types of mesodermal origin
(10). MSC provide growth factors to progenitor cells that boost
their regenerative processes (11, 12). More than 800MSC-related
studies are registered at http://clinicaltrials.gov on December
2018 and some of them have shown promising results in the
treatment of kidney injury from different etiologies (13).
Abbreviations: EC, Endothelial cells; hMSC, Human mesenchymal stromal cells;
HUVEC, Human umbilical cord endothelial cells; MSC, Mesenchymal stromal
cells; NADH, Nicotinamide adenine dinucleotide; NMP, Normothermic machine
perfusion; PAOEC, Porcine aortic endothelial cells; pMSC, Porcine mesenchymal
stromal cells; ROS, Reactive oxygen species; XTT, 2,3-Bis-(2-Methoxy-4-Nitro-5-
Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide.
MSC are usually intravenously (IV) administered, which
inevitably leads to accumulation in the lungs and poor delivery
to target organs (14, 15). Obviously, delivery of MSC to the
target organ while perfused on an ex vivo stand-alone circuit
may overcome this dilemma. The idea to combine NMP and
MSC therapy has generated an interest in the area of kidney
transplantation (16–18). It is however unknown whether MSCs
are compatible with the conditions of NMP.
In addition, a significant difference exists between preparation
of therapeutic MSC for pre-clinical vs. clinical trials. In pre-
clinical experiments, MSC are cultured in vitro and administered
directly from the culture flask to laboratory animals when the
cells are ready for infusion. In the human setting, large numbers
of MSC are needed to treat a patient and cells are often produced
at locations distant from the place of administration. This
requires storage of cells in a frozen state and infusion following
a delicate thawing process (13). Existing literature points out
that frozen-thawed human MSC (hMSC) have an altered gene
expression profile compared to cells directly retrieved from
culture flasks (19), while it also has been shown that MSC
immunoregulatory properties may be impaired by the freeze-
thawing process (20). If the properties of MSC are impaired after
the thawing process, this would mean that the results of human
studies may not have the expected outcome.
It has been described that MSC from different species will
exert the same actions through different mechanisms, which
could affect the efficacy ofMSC in various animalmodels (21, 22).
Human and non-human primate MSC (23, 24) show marked
similarities with respect to their biological properties, but it
is unknown whether their therapeutic effects are comparable.
Porcine models are very suitable for organ transplant and
preservation studies due to the similarity in size and physiology
between human and pig. It is however unknown whether
MSC from human and pig behave in the same manner under
NMP conditions.
With the questions above in mind, it is important to simulate
conditions of NMP and assess their effect on MSC. We have
evaluated the effect of the bespoke perfusate required for NMP in
combination with the condition of fresh vs. frozen-thawed MSC
in suspension using cells from porcine (pMSC) and from human
(hMSC) origin.
MATERIALS AND METHODS
Isolation and Culture of Human and
Porcine MSC and Endothelial Cells
hMSC were isolated from subcutaneous adipose tissue from
healthy human kidney donors (n = 5) that became available
during kidney donation procedures after obtaining written
informed consent as approved by the Medical Ethical Committee
of the Erasmus University Medical Center Rotterdam (MEC-
2006-190). pMSCwere isolated from subcutaneous adipose tissue
(n= 5) collected frommale pigs, which were subjected to surgery
for teaching purposes, as a waste product. hMSC and pMSC
were isolated as described previously (25) and phenotypically
characterized by the expression of CD29, CD44, CD90 and the
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absence of CD31 and CD45. Human umbilical vein endothelial
cells (HUVEC) were purchased from Lonza (Basel, Switzerland)
and porcine aortic endothelial cells (PAOEC) were purchased
from Cell Applications Inc. (San Diego, CA, USA).
Both hMSC and pMSC were cultured in minimum essential
medium-α (MEM-α) (Sigma Aldrich, St. Louis, MO, USA)
supplemented with penicillin (100 IU/ml), streptomycin (100
mg/ml) (1% P/S; Lonza), 2mM L-glutamine (Lonza) and
15% fetal bovine serum (FBS; Lonza). HUVEC were cultured
in endothelial growth medium 2 (PromoCell, Heidelberg,
Germany). PAOEC were cultured in porcine endothelial cell
media (Cell Applications, Inc.). MSC were used at passage 3-6,
HUVEC were used at passage 4-8 and PAOEC at passage 3-6.
Perfusion Fluid
The perfusion fluid was a RBC-based solution with albumin as
colloid adapted from NMP experiments used by several groups
and allowing stable NMP of kidneys (4, 26, 27). The composition
of the perfusion fluid is listed in Table 1.
Survival of MSC in Perfusion Fluid
MSC were trypsinized from the culture flasks at 90% confluency
or thawed after cryopreservation and re-suspended either in
complete culture medium or perfusion fluid at a concentration
of 500,000 MSC/ml. MSC were incubated in perfusion fluid in
polypropylene tubes to avoid attachment of MSC to plastic. After
30min or 2 h in suspension, MSC were submitted to a RBC lysis
process to remove the large amount of RBC present in perfusion
fluid. MSC incubated in suspension with culture medium were
also subjected to RBC lysis to treat both groups in the same way.
Briefly, 3ml of red blood cell lysis buffer (Invitrogen, Carlsbad,
CA, USA) was added to MSC and incubated for 20min at room
temperature (RT). MSC were then washed with PBS and stained
with Annexin-V (PE) and ViaProbe (PercP) to assess the number
of early and late apoptotic cells. Perfusion fluid was also added
to attached MSC and incubated for the same time and then
trypsinized and stained as mentioned. Cells were analyzed by
flow cytometry (FACS Canto II, BD Biosciences, NJ, USA) and
data were analyzed using Kaluza Analysis 1.5a (Beckman Coulter,
Brea, CA, USA).
TABLE 1 | Composition of perfusion fluid.
Red blood cells (Hematocrit 0.4 L/L)
Sodium (94.3 mmol/L)
Calcium (1.46 mmol/L)
Potassium (1.48 mmol/L)
Lactate (5.33 mmol/L)
Bicarbonate (26 mmol/L)
Albumin (19.1 g/L)
Glucose (2.93 mmol/L)
Mannitol (15.87 mg/L)
Creatinine (109.5 mg/L)
Amoxicillin (43.5 mmol/L)
Clavulanic Acid (16.1 mmol /L)
Mitochondrial Activity and Oxidative Stress
of MSC
MSC metabolic activity was measured by a colorimetric
assay based on the reduction of XTT [2,3-Bis-(2-Methoxy-
4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide] by
nicotinamide adenine dinucleotide (NADH) (ThermoFisher,
Manhattan, NY, USA). The reagent is reduced by NADH
produced during mitochondrial metabolism which results
in a color change of the XTT reagent detectable by a
spectrophotometer. The concentration of the reagent is
measured by absorbance measured at a wavelength of
450–500 nm. This assay was performed on MSC that
were in suspension for 30 and 120min in perfusion fluid
or culture medium and on attached MSC. In addition,
oxidative stress of MSC was measured using CellRox
reagent (ThermoFisher) according to the manufacturer’s
manual. CellRox is oxidized by reactive oxygen species
(ROS) and emits a fluorescent signal that is measured by
flow cytometry.
Proliferation of MSC
In order to assess the effects of perfusion fluid on
cell proliferation, MSC were fluorescently labeled with
carboxyfluorescein succinimidyl ester (CFSE) (ThermoFisher)
which was added to the cells at a concentration of 5mM.
The cells were then incubated at 37◦C for 15min in the dark.
Staining was stopped by the addition of twice the volume of
FBS-containing culture medium and incubated for 5min at RT.
Cells were washed and exposed to perfusion fluid for 30 and
120min at 37◦C. After incubation with perfusion fluid, MSC
were seeded in a 6-well-plate with regular culture medium and
proliferation was measured at 24, 48, and 72 h by flow cytometry.
Release of Cytokines
A custom-made Luminex Multiplex Assay (R&D Systems,
Minneapolis, MN, USA) was designed to measure the release
of the following cytokines and growth factors by hMSC after
incubation with perfusion fluid:
Angiopoietin-1 (ANG-1), Angiopoietin-2 (ANG-2),
epidermal growth factor (EGF), hepatocyte growth factor
(HGF), interferon-gamma (IFN-γ), interleukin 10 (IL-10),
interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-
1), programmed death ligand 1 (PD-L1), platelet derived growth
factor AA (PDGFAA), Thrombospondin-2, tissue inhibitor
of metalloproteases 1 (TIMP-1), tumor necrosis factor alpha
(TNF-α), soluble tumor necrosis factor receptor 1 (sTNF-RI)
and vascular endothelial growth factor (VEGF).
Subconfluent (90%) cultures of hMSC were washed and
cells were incubated in perfusion fluid for 30 and 120min.
Wells were washed again and culture medium was added. After
24 h supernatants were retrieved and the array was performed
according to the manufacturer’s protocol. Fluorescence was
measured on a Luminex 100/200 system (Luminex, Austin, TX,
USA) using Xponent software. Due to the lack of pig-specific
reagents this assay was only performed in with hMSC.
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Adhesion of MSC to Endothelial Cells
Confluent monolayers of endothelial cells were cultured in 24-
well-plates. Culture medium was replaced by either a 1:1 mix
of MSC and endothelial cell (EC) medium or perfusion fluid.
200,000 MSC were fluorescently-labeled with PKH26 (Sigma)
and added to each well. After 10, 30, 60, 120, and 240min
supernatant was removed and wells were washed to eliminate all
non-adherent MSC. Attached cells were trypsinized and analyzed
by flow cytometry. Fluorescent signal detected by flow cytometry
allowed the determination of the percentage of MSC attached.
RESULTS
Cryopreserved MSC Show Reduced
Survival in Perfusion Fluid and Medium
To examine the survival of MSC, fresh and cryopreserved MSC
were incubated in suspension in perfusion fluid. Survival rates
of freshly cultured and thawed pMSC were <40% after 30min
and decreased to 30% after 2 h in culture medium. Perfusion
fluid had no negative impact on pMSC survival compared to
culture medium except on thawedMSC after 30min in perfusion
(Figure 1A). hMSCwere more resistant to suspension conditions
than pMSC. Freshly cultured hMSC showed more than 95%
survival in medium and in perfusion fluid. However, a significant
decrease in survival to approximately 70% was observed for
cryopreserved hMSC in perfusion fluid and in culture medium
compared to fresh MSC. Perfusion fluid reduced survival of fresh
hMSC after 2 h only minimally when compared to regular culture
medium (Figure 1B).
MSC Show Impaired Adhesion to
Endothelial Cells in Perfusion Fluid
To assess the function of surviving MSC in perfusion fluid, the
capacity of MSC to adhere to EC was tested. In culture medium,
fresh and thawed pMSC started to attach to PAOEC already
10min after seeding. After 4 h, almost 100% of freshly cultured
pMSC were attached to PAOEC while only 80% of thawed
pMSC adhered (Figure 2A). Perfusion fluid strongly reduced the
capacity of pMSC to attach to PAOEC regardless if they were
fresh or thawed cells. Fresh hMSC adhesion to HUVEC was
higher than 95% after 4 h in culture medium. In perfusion fluid,
60% of fresh hMSC were able to attach after 4 h. Cryopreserved
hMSC showed 80% attachment in culture medium after 4 h and
<50% of cryopreserved hMSC attached to HUVEC in perfusion
fluid (Figure 2B). In general, thawed MSC showed a decreased
capacity to attach to EC compared to fresh MSC, a difference that
became more prominent in perfusion fluid.
Thawed MSC Express Higher Levels of
ROS
The reduced adhesion of thawed MSC to EC could be explained
by higher oxidative stress of MSC after the thawing process. The
accumulation of ROS derived from the thawing process might
induce damage in thawedMSC. An increased production of ROS
by thawed pMSC and hMSC was observed at 30min and 2 h
after thawing both in medium and perfusion fluid (Figure 3A).
Thawed hMSC produced a higher level of ROS than pMSC
whereas ROS production in hMSC was boosted in perfusion
fluid (Figure 3B). Thawed hMSC had elevated concentrations of
ROS compared to fresh hMSC. These results indicate that freeze-
thawing and perfusion fluid affects ROS production in pMSC and
hMSC in the first hours after thawing.
Metabolic Activity of Mitochondria Is
Reduced in Thawed MSC
ROS production leads to mitochondrial damage which results in
reduced metabolic activity of cells. It is possible that MSC survive
in suspension but are less metabolically active, whichmay explain
the different capacity of MSC to adhere to EC after thawing
or in perfusion fluid. To determine the effect of perfusion fluid
and the freeze-thawing procedure on MSC metabolic activity,
the conversion of XTT to its reduced state by mitochondria was
measured in MSC. pMSC mitochondrial activity showed to be
very stable and was not affected by cryopreservation (Figure 3C).
However, perfusion fluid induced a small increase in activity
after 30min. Fresh hMSC showed a 2-fold higher mitochondrial
activity than pMSC. Furthermore, fresh hMSC were more active
than their thawed counterparts. After 30min in perfusion fluid,
fresh hMSC showed increased mitochondrial activity compared
to culture medium (Figure 3D).
Freeze-Thawing Affects Proliferation of
hMSC but Not pMSC
Proliferation of MSC was measured after initial incubation in
suspension in perfusion fluid or medium for 30min and 120min,
followed by 72 h culture in culture medium. Incubation in
perfusion fluid did not affect pMSC proliferation (Figures 4A,B).
Freshly cultured hMSC proliferated more than thawed hMSC
after incubation in perfusion fluid or medium (Figures 4C,D).
Perfusion Fluid Increases the Proliferation
of Attached MSC
MSC are adherent tissue cells and the suspension conditions
in the previous experiments may affect their phenotype and
function. To examine how adherent MSC respond to perfusion
fluid, morphology, survival, metabolic activity and proliferation
of attached MSC were studied. The morphology of MSC
in culture was not affected after 30min or 2 h culture in
perfusion fluid (Figures 5A–J). Adherent pMSC and hMSC
showed increased survival in perfusion fluid compared to MSC
in suspension. Survival of adherent pMSC was higher than 80%
in culture medium and perfusion fluid (Figures 6A,B) compared
to a maximum of 40% survival in suspension (Figure 1A).
hMSC showed 78% survival after 2 h in suspension in perfusion
fluid, but when they were attached, survival after 2 h was 93%.
No differences in survival were observed between perfusion
fluid and culture medium on attached MSC (Figures 6A,B). No
significant effect of perfusion fluid on mitochondrial activity
was observed for attached MSC, although there was a trend
toward a decline in activity of pMSC and hMSC over time when
cultured in perfusion fluid (Figures 6C,D). Pre-incubation of
attached pMSC in perfusion fluid increased their proliferation
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FIGURE 1 | Effect of perfusion fluid on survival of fresh and thawed pMSC and hMSC in suspension. (A) Perfusion fluid had minimal effect on pMSC survival
compared to medium. (B) Perfusion fluid had minimal effects on hMSC survival. Thawed hMSC showed a lower survival in suspension compared to fresh hMSC.
Perfusion fluid reduced survival of hMSC after 2 h (n = 5). Results are shown as means ± SD. *p < 0.05; **p < 0.01.
FIGURE 2 | Adhesion of fresh and cryopreserved pMSC and hMSC to EC in medium and perfusion fluid. (A) pMSC attachment to PAOEC over time in culture
medium. pMSC show reduced binding to PAOEC in perfusion fluid. Thawed pMSC showed a further reduced ability to bind to EC in perfusion fluid. (B) Thawed hMSC
showed reduced attachment to HUVEC compared to fresh hMSC either in culture medium or perfusion fluid (n = 5). Results are shown as means ± SD. **p < 0.01.
after 24 h compared to culture medium. This effect was observed
only after 120min pre-incubation in perfusion fluid for hMSC
(Figures 6E,F).
Secretory Profile of MSC Is Not Affected by
Culture in Perfusion Fluid
The secretion of growth factors and cytokines is an important
mechanism of action of MSC. To examine whether perfusion
fluid would preserve the secretory profile of adherent hMSC and
furthermore whether perfusion fluid induced an inflammatory
response in hMSC, hMSC were incubated in perfusion fluid
for 30min or 2 h and growth factor and cytokine secretion
was analyzed. We observed that the secretion of the angiogenic
factors VEGF, PDGF, ANG-1, HGF and Thr2 was unaffected
in perfusion fluid (Figures 7A–E). Inflammatory cytokines IL-6
and MCP-1 were increased 2-fold and 10-fold, respectively, in
perfusion fluid (Figures 8A,B).
DISCUSSION
In the present work we have assessed the effect of a period of
incubation in a perfusion fluid required for robust longer term
ex vivo NMP of kidneys on MSC of both pig and human origin.
Our work involved the use of cryopreserved MSC for logistic
purposes, suspension conditions to deliver MSC via the renal
artery using NMP and the use of an RBC-based perfusion fluid
which may affect the survival and function of MSC. In order
to mimic the conditions of a potential novel MSC therapy to
stimulate the repair of injured kidneys while these are connected
to NMP, MSC were thawed after cryopreservation and incubated
in perfusion fluid in suspension. Actual infusion of MSC using
NMPwas not carried out as the purpose of the study was to assess
the individual effect of each of the aforementioned conditions
separately. In case that NMP conditions did not support MSC
survival and function, future planned experimentation in the
NMP setup could have been stopped, reducing economic and
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FIGURE 3 | Perfusion fluid and thawing after cryopreservation increase ROS production and reduce metabolic activity in MSC. (A) ROS production in fresh and
frozen-thawed pMSC suspended in culture medium or in perfusion fluid. (B) ROS production in fresh and in frozen-thawed hMSC suspended in culture medium or in
perfusion fluid. (C) Metabolic activity measured by XTT reduction by NADH of fresh and frozen-thawed pMSC after 30min and 2 h incubation in perfusion fluid. (D)
Metabolic activity measured by XTT reduction by NADH of fresh and frozen-thawed hMSC after 30min and 2 h incubation in perfusion fluid (n = 5). Results are shown
as means ± SD. *p < 0.05; **p < 0.01.
time costs. Nevertheless, the results of this study allow to take
the next step and study MSC infusion through an NMP system,
which is already planned to be carried out.
In the field of clinical MSC therapy, temporary
cryopreservation and thawing along with vehicle solutions
to deliver the therapy are important factors that can determine
the success of MSC therapy (20, 28–30). The handling time
until administration will have an impact on the survival and
function of MSC. Survival of MSC is affected by the composition
of storage media (31) and cytokine secretion profile of MSC can
be altered, affecting MSC properties such as angiogenic potential
(32). Our results show that the particular perfusion fluid used for
our experiment is not detrimental for the secretion of angiogenic
factors by hMSC.
The bespoke NMP perfusion fluid used in this study supports
the survival of pig and human MSC. However, the function
and metabolism of these cells are affected by the suspension
conditions MSC were kept in. Specifically, perfusion fluid
inhibited the adhesion of pMSC in suspension to PAOEC
and hMSC to HUVEC. MSC have the capacity to adhere to
endothelial cells in vitro under flow conditions as previously
shown, especially when endothelial cells have been treated to
recreate an inflammatory environment. Attachment of MSC to
endothelial cells was shown to be reduced under flow compared
to static conditions (33). Being in suspension in different
clinically used storage solutions such as physiologic saline can
influence the survival of MSC (31) and the composition of the
solution that MSC are kept in modifies their metabolism and
function (34, 35). Therefore, it can be deducted that the effect
of MSC therapy delivered to renal grafts during ex vivo NMP
will depend, among other factors, upon the composition of the
perfusion fluid. A recent study perfused kidneys for 24 h using
NMP. They infused MSC at different concentrations however,
after 24 h they found 95% of infused MSC back in their perfusion
solution (36), which indicate a very diminished adhesion capacity
of MSC toward endothelial cells. Our results are consistent
with existing literature and indicate that the composition of
the perfusion fluid as well as the infusion process affects the
functional properties and delivery efficiency of the final MSC
product. Therefore, further knowledge need to be obtained
regarding the effects of perfusion conditions on MSC delivery to
the injured kidney.
Human and porcine MSC showed a negative response at
several levels to cryopreservation, thawing and re-suspension in
perfusion fluid. The effect of cryopreservation and thawing of
hMSC has been a concern for the community as it can decrease
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FIGURE 4 | Effect of perfusion fluid and freeze-thawing on proliferation of MSC. pMSC and hMSC were incubated in perfusion fluid for 30 and 120min and
proliferation was measured after subsequent culturing in medium after 72 h. (A) pMSC proliferation was not affected by incubation in perfusion fluid for 30min. (B)
pMSC in perfusion fluid proliferated less than pMSC in culture medium. (C,D) Fresh hMSC proliferated more than thawed hMSC and perfusion fluid did not have an
effect on fresh hMSC proliferation. Thawed cells in perfusion fluid were the least proliferative (n = 5). Results are shown as means ± SD. *p < 0.05; **p < 0.01.
FIGURE 5 | Effect of perfusion fluid on morphology of attached MSC. (A) pMSC in regular culture medium. (B,C) pMSC in culture medium or perfusion fluid,
respectively for 30min. (D,E) pMSC cultured in culture medium or perfusion fluid, respectively for 120min. (F) hMSC in regular culture medium. (G,H) hMSC cultured
in culture medium or perfusion fluid, respectively for 30min. (I,J) hMSC cultured in culture medium or perfusion fluid, respectively for 120min.
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FIGURE 6 | Effect of perfusion fluid on attached MSC. Survival of attached pMSC (A) and hMSC (B) after 30min in perfusion fluid. (C,D) Metabolic activity of
attached pMSC (C) and hMSC (D) after 30min in perfusion fluid measured by reduction of XTT. (E,F) Proliferation of attached pMSC (E) and hMSC (F) after 30 in
perfusion fluid. Cells were trypsinized and re-seeded in a culture flask. Proliferation after 24 h was determined by CFSE fluorescence (n = 5). Results are shown as
means ± SD. *p < 0.05; **p < 0.01.
the presumed efficacy of MSC therapy (19, 28, 30, 37). Our
results confirmed this concern. It has recently been published
that freezing-thawing MSC increases the production of ROS
and compromises membrane stability and homeostasis in pMSC
(38), which is also supported by our data. Viability of MSC
is a key factor for treatments that require an active role of
MSC. However, inactive MSC have been shown to retain their
immunomodulatory properties (14, 39, 40). Therefore, the aim
of MSC therapy dictates the required characteristics of MSC.
In vivo, MSC are tissue resident cells and are found in
perivascular niches in a wide variety of tissues (41–43). In vitro,
MSC are strictly grown as adherent cells, and for this reason
MSC are cultured allowing plastic adherence to expand them
(10). We demonstrated that the poor performance of MSC in
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FIGURE 7 | Production of angiogenic factors by hMSC in culture medium and perfusion fluid. MSC were incubated in perfusion fluid for 30 or 120min, washed and
replaced by culture medium for 24 h. The secretion of angiogenic and growth factors was not affected by perfusion fluid. (A–E) Concentration of secreted VEGF,
PDGF, ANG1, HGF and Thr2, respectively (n = 5). Results are shown as mean ± SD.
FIGURE 8 | Production of inflammatory cytokines by hMSC in culture medium and perfusion fluid. MSC were incubated in perfusion fluid for 30 or 120min, washed
and replaced by culture medium for 24 h. (A) The secretion of IL-6 shows tendency to increase by perfusion fluid. (B) The secretion of MCP-1 by MSC is increased
after incubation in perfusion fluid (n = 5). Results are shown as means ± SD. **p < 0.01.
perfusion fluid was primarily due to the fact that they were
in suspension. Survival of both pig and human MSC cultured
in adherent conditions in perfusion fluid was higher than that
of MSC kept in suspension, suggesting a protective effect of
adherence. Mitochondrial activity, however, was similar in MSC
in suspension and attached, suggesting that MSC are active
also in suspension. Proliferation of pMSC was increased after
exposure to perfusion fluid which could be a response to a
specific component of the perfusion fluid (31). These results
suggest that the nature ofMSCmake themmore vulnerable when
they are in suspension and therefore, it should be minimized
when they are administered as therapy. Being in suspension in
perfusion is, however, a transient condition in the process ofMSC
delivery using NMP. Presumably, when MSC are delivered to
the injured kidney, the damaged tissue microenvironment will
help the MSC to be retained and produce regenerative factors
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as previously shown (44–46). We have shown that after being
in contact with perfusion solution MSC can recover, proliferate
and be metabolically active. In addition, the secretory profile of
angiogenic factor by hMSC is not affected by perfusion fluid.
Therefore, this is a promising result that hints MSC maintain
their reparative potential after delivery using NMP.
Cryopreservation, thawing and suspension of MSC are
inevitable conditions to infuse GMP-grade MSC to kidney
transplants via NMP. These conditions are necessary to bridge
differences in time and location between MSC preparation
and NMP. The disadvantageous effect of these conditions on
MSC has to be taken into account for the evaluation of the
suitability of MSC therapy for NMP. In order to improve the
viability of MSC in NMP conditions, the composition of the
perfusion fluidmay be adapted to provide better support forMSC
survival. Another possibility is to recover MSC after thawing
under favorable conditions to improve the resistance of MSC to
NMP. An alternative would be to take the loss of MSC under
NMP conditions into account and use higher numbers of cells,
although the effect of administering large numbers of non-viable
MSC to the kidney is uncertain.
Pre-clinical work in the field of transplantation is often
performed using porcine models to better understand the
possible behaviors of new therapies in patients. Therefore, we
investigated MSC of porcine and human origin in order to
determine if results can be translated. The response to the
thawing process as well as to suspension conditions and perfusion
fluid was quite different between MSC from both origins for
the parameters studied. We are aware that differences could be
related not only to species but also to age and gender, as well as
site of adipose tissue harvesting from the donor. However, our
results indicate that caution should be taken when interpreting
in vitro studies with porcine cells toward the behavior of human
cells. A safe translation from swine pre-clinical models to
clinical studies is challenging when results are not reproducible
between species.
Summarizing, NMP conditions will affect MSC but show
sufficient support of their function and survival to consider MSC
administration through NMP as a viable option in pursuit of a
potentially beneficial cell therapy for the regeneration of injured
organs. After these essential preliminary experiments, further
study is now underway to determine the best way of joining these
two exciting techniques in an optimal manner.
AUTHOR CONTRIBUTIONS
BJ, CB, ME, RP, and MH: conception of the study; JS, AM, and
MH: designed the experiments; JS: performed the experiments
and the analysis of the data; JS, AM, and MH: interpreted
the data. All authors contributed to writing and reviewing the
manuscript.
FUNDING
TheMePEP project is funded by the Lundbeck Foundation under
grant application no R198-2015-184.
REFERENCES
1. Hippen B, Ross LF, Sade RM. Saving lives is more important
than abstract moral concerns: financial incentives should be used
to increase organ donation. Ann Thorac Surg. (2009) 88:1053–61.
doi: 10.1016/j.athoracsur.2009.06.087
2. Ojo AO. Expanded criteria donors: process and outcomes. Semin Dial. (2005)
18:463–8. doi: 10.1111/j.1525-139X.2005.00090.x
3. Nagaraja P, Roberts GW, Stephens M, Horvath S, Kaposztas Z, Chavez
R, et al. Impact of expanded criteria variables on outcomes of kidney
transplantation from donors after cardiac death. Transplantation. (2015)
99:226–31. doi: 10.1097/TP.0000000000000304
4. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo
normothermic perfusion: the first clinical study. Am J Transplant. (2013)
13:1246–52. doi: 10.1111/ajt.12179
5. Weissenbacher A, Lo Faro L, Boubriak O, Soares MF, Roberts IS, Hunter
JP, et al. Twenty-four hour normothermic perfusion of discarded human
kidneys with urine recirculation. Am J Transplant. (2018) 19:178–92.
doi: 10.1111/ajt.14932
6. Hosgood SA, Thompson E, Moore T, Wilson CH, Nicholson ML.
Normothermic machine perfusion for the assessment and transplantation of
declined human kidneys from donation after circulatory death donors. Br J
Surg. (2018) 105:388–94. doi: 10.1002/bjs.10733
7. Kaths JM, Hamar M, Echeverri J, Linares I, Urbanellis P, Cen JY, et al.
Normothermic ex vivo kidney perfusion for graft quality assessment prior to
transplantation. Am J Transplant. (2018) 18:580–9. doi: 10.1111/ajt.14491
8. Smith SF, Adams T, Hosgood SA, Nicholson ML. The administration
of argon during ex vivo normothermic perfusion in an experimental
model of kidney ischemia-reperfusion injury. J Surg Res. (2017) 218:202–8.
doi: 10.1016/j.jss.2017.05.041
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
et al. Multilineage potential of adult human mesenchymal stem cells. Science.
(1999) 284:143–7. doi: 10.1126/science.284.5411.143
10. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause
D, et al. Minimal criteria for defining multipotent mesenchymal stromal
cells. The International Society for Cellular Therapy position statement.
Cytotherapy. (2006) 8:315–7. doi: 10.1080/14653240600855905
11. Kim HK, Lee SG, Lee SW, Oh BJ, Kim JH, Kim JA, et al. A subset of
paracrine factors as efficient biomarkers for predicting vascular regenerative
efficacy of mesenchymal stromal/stem cells. Stem Cells. (2018) 37:77–88.
doi: 10.1002/stem.2920
12. Azhdari Tafti Z, Mahmoodi M, Hajizadeh MR, Ezzatizadeh V, Baharvand H,
Vosough M, et al. Conditioned media derived from human adipose tissue
mesenchymal stromal cells improves primary hepatocyte maintenance. Cell
J. (2018) 20:377–87. doi: 10.22074/cellj.2018.5288
13. Reinders MEJ, van Kooten C, Rabelink TJ, de Fijter JW.Mesenchymal stromal
cell therapy for solid organ transplantation. Transplantation. (2018) 102:35–
43. doi: 10.1097/TP.0000000000001879
14. de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS,
et al. Immunomodulation by therapeutic Mesenchymal Stromal Cells (MSC)
is triggered through phagocytosis of MSC by monocytic cells. Stem Cells.
(2018) 36:602–15. doi: 10.1002/stem.2779
15. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt
HJ, et al. Mesenchymal stem cells are short-lived and do not migrate
beyond the lungs after intravenous infusion. Front Immunol. (2012) 3:297.
doi: 10.3389/fimmu.2012.00297
16. Sierra-Parraga JM, Eijken M, Hunter J, Moers C, Leuvenink H, Moller B, et al.
Mesenchymal stromal cells as anti-inflammatory and regenerative mediators
for donor kidneys during normothermic machine perfusion. Stem Cells Dev.
(2017) 26:1162–70. doi: 10.1089/scd.2017.0030
Frontiers in Immunology | www.frontiersin.org 10 April 2019 | Volume 10 | Article 765
Sierra Parraga et al. Effect of NMP Conditions on MSC
17. Weissenbacher A, Hunter, J. Normothermic machine perfusion
of the kidney. Curr Opin Organ Transplant. (2017) 22:571–6.
doi: 10.1097/MOT.0000000000000470
18. Hamar M, Selzner, M. Ex-vivo machine perfusion for kidney
preservation. Curr Opin Organ Transplant. (2018) 23:369–74.
doi: 10.1097/MOT.0000000000000524
19. Hoogduijn MJ, de Witte SF, Luk F, van den Hout-van Vroonhoven MC,
Ignatowicz L, Catar R, et al. Effects of freeze-thawing and intravenous infusion
on mesenchymal stromal cell gene expression. Stem Cells Dev. (2016) 25:586–
97. doi: 10.1089/scd.2015.0329
20. Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke
L, et al. Do cryopreserved mesenchymal stromal cells display impaired
immunomodulatory and therapeutic properties? Stem Cells. (2014) 32:2430–
42. doi: 10.1002/stem.1729
21. Lohan P, Treacy O, Morcos M, Donohoe E, O’Donoghue Y, Ryan AE,
et al. Interspecies incompatibilities limit the immunomodulatory effect of
human mesenchymal stromal cells in the rat. Stem Cells. (2018) 36:1210–5.
doi: 10.1002/stem.2840
22. Ling W, Zhang J, Yuan Z, Ren G, Zhang L, Chen X, et al. Mesenchymal stem
cells use IDO to regulate immunity in tumor microenvironment. Cancer Res.
(2014) 74:1576–87. doi: 10.1158/0008-5472.can-13-1656
23. Pogozhykh O, Pogozhykh D, Neehus AL, Hoffmann A, Blasczyk R,
Muller, T. Molecular and cellular characteristics of human and non-
human primate multipotent stromal cells from the amnion and bone
marrow during long term culture. Stem Cell Res Ther. (2015) 6:150.
doi: 10.1186/s13287-015-0146-6
24. Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, et al. Biologic
properties of mesenchymal stem cells derived from bone marrow and adipose
tissue. J Cell Biochem. (2006) 99:1285–97. doi: 10.1002/jcb.20904
25. Hoogduijn MJ, Crop MJ, Peeters AM, Van Osch GJ, Balk AH, Ijzermans
JN, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem
cells have immunomodulatory capacities. Stem Cells Dev. (2007) 16:597–604.
doi: 10.1089/scd.2006.0110
26. Hosgood SA, Nicholson ML. First in man renal transplantation after
ex vivo normothermic perfusion. Transplantation. (2011) 92:735–8.
doi: 10.1097/TP.0b013e31822d4e04
27. Hosgood SA, Barlow AD, Hunter JP, Nicholson ML. Ex vivo normothermic
perfusion for quality assessment of marginal donor kidney transplants. Br J
Surg. (2015) 102:1433–40. doi: 10.1002/bjs.9894
28. Moll G, Geissler S, Catar R, Ignatowicz L, Hoogduijn MJ, Strunk D, et al.
Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or
key to unleash the full clinical potential of MSC therapy? Adv Exp Med Biol.
(2016) 951:77–98. doi: 10.1007/978-3-319-45457-3_7
29. Francois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK,
Galipeau, J. Cryopreserved mesenchymal stromal cells display impaired
immunosuppressive properties as a result of heat-shock response and
impaired interferon-gamma licensing. Cytotherapy. (2012) 14:147–52.
doi: 10.3109/14653249.2011.623691
30. Chinnadurai R, Garcia MA, Sakurai Y, Lam WA, Kirk AD, Galipeau J,
et al. Actin cytoskeletal disruption following cryopreservation alters the
biodistribution of human mesenchymal stromal cells in vivo. Stem Cell
Reports. (2014) 3:60–72. doi: 10.1016/j.stemcr.2014.05.003
31. Nofianti CE, Sari IN, Marlina, Novialdi, Pawitan JA. Temporary storage
solution for adipose derived mesenchymal stem cells. Stem Cell Investig.
(2018) 5:19. doi: 10.21037/sci.2018.05.04
32. Parsha K, Mir O, Satani N, Yang B, Guerrero W, Mei Z, et al. Mesenchymal
stromal cell secretomes are modulated by suspension time, delivery vehicle,
passage through catheter, and exposure to adjuvants. Cytotherapy. (2017)
19:36–46. doi: 10.1016/j.jcyt.2016.10.006
33. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E,
et al. Mesenchymal stem cells display coordinated rolling and
adhesion behavior on endothelial cells. Blood. (2006) 108:3938–44.
doi: 10.1182/blood-2006-05-025098
34. Xia W, Li H, Wang Z, Xu R, Fu Y, Zhang X, et al. Human platelet lysate
supports ex vivo expansion and enhances osteogenic differentiation of human
bonemarrow-derivedmesenchymal stem cells.Cell Biol Int. (2011) 35:639–43.
doi: 10.1042/CBI20100361
35. de Witte SFH, Lambert EE, Merino A, Strini T, Douben H, O’Flynn L,
et al. Aging of bone marrow- and umbilical cord-derived mesenchymal
stromal cells during expansion. Cytotherapy. (2017) 19:798–807.
doi: 10.1016/j.jcyt.2017.03.071
36. Brasile L, Henry N, Orlando G, Stubenitsky, B. Potentiating Renal
Regeneration using Mesenchymal Stem Cells. Transplantation. (2018).
103:307–13. doi: 10.1097/TP.0000000000002455
37. Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller
EK, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell
mediated apoptosis which is partly rescued by ifngamma licensing. Stem Cells.
(2016) 34:2429–42. doi: 10.1002/stem.2415
38. Gurgul A, Romanek J, Pawlina-Tyszko K, Szmatola T, Opiela, J. Evaluation
of changes arising in the pig mesenchymal stromal cells transcriptome
following cryopreservation and Trichostatin A treatment. PLoS ONE. (2018)
13:e0192147. doi: 10.1371/journal.pone.0192147
39. Luk F, de Witte S, Korevaar SS, Roemeling-van Rhijn M, Franquesa M, Strini
T, et al. Inactivated mesenchymal stem cells maintain immunomodulatory
capacity. Stem Cells Dev. (2016) 25:1342–54. doi: 10.1089/scd.2016.0068
40. Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung
TS, et al. Apoptosis in mesenchymal stromal cells induces in vivo
recipient-mediated immunomodulation. Sci Transl Med. (2017) 9:416.
doi: 10.1126/scitranslmed.aam7828
41. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated
source of stem cells for biotechnology. Trends Biotechnol. (2006) 24:150–4.
doi: 10.1016/j.tibtech.2006.01.010
42. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al.
Adult cardiac stem cells aremultipotent and support myocardial regeneration.
Cell. (2003) 114:763–76. doi: 10.1016/S0092-8674(03)00687-1
43. GriffithsMJ, Bonnet D, Janes SM. Stem cells of the alveolar epithelium. Lancet.
(2005) 366:249–60. doi: 10.1016/S0140-6736(05)66916-4
44. Marquez-Curtis LA, Janowska-Wieczorek, A. Enhancing the migration ability
of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. Biomed Res
Int. (2013) 2013:561098. doi: 10.1155/2013/561098
45. Ryu CH, Park SA, Kim SM, Lim JY, Jeong CH, Jun JA, et al. Migration
of human umbilical cord blood mesenchymal stem cells mediated by
stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal
transduction pathways. Biochem Biophys Res Commun. (2010) 398:105–10.
doi: 10.1016/j.bbrc.2010.06.043
46. Talkenberger K, Cavalcanti-Adam EA, Voss-Bohme A, Deutsch, A.
Amoeboid-mesenchymal migration plasticity promotes invasion only
in complex heterogeneous microenvironments. Sci Rep. (2017) 7:9237.
doi: 10.1038/s41598-017-09300-3
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Sierra Parraga, Rozenberg, Eijken, Leuvenink, Hunter, Merino,
Moers, Møller, Ploeg, Baan, Jespersen and Hoogduijn. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 11 April 2019 | Volume 10 | Article 765
